FIELD: biotechnology.
SUBSTANCE: invention can be used in medical practice. The invention discloses novel antibody-drug conjugates (ADCs) containing an anti-MUC1 antibody.
EFFECT: such conjugates demonstrate significant antitumor efficacy against various malignancies with cells expressing TA-MUC1 and the conjugates can be used in therapy.
49 cl, 10 ex, 3 tbl, 19 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST MUC1 | 2019 |
|
RU2792347C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
